US-based biopharmaceutical company BeyondSpring has enrolled the first patient in its Phase Ib/II trial of plinabulin combined with nivolumab to treat metastatic non-small-cell lung cancer (NSCLC).

Plinabulin is a small molecule agent developed with multiple mechanisms of action that are the immune enhancing mechanism, tumour vasculature targeting, and activating c-Jun N-terminal protein kinase (JNK) pathway resulting in cancer cell apoptosis.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Nivolumab is a fully human immunoglobulin (Ig) G4 monoclonal antibody that acts against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities.

The open-label, dose-escalation, two-part, single-site Phase Ib/II trial is planning to involve about 12 patients in the Phase Ib portion and a total of 20 patients in the Phase II portion.

"The company is currently conducting a global Phase III trial of plinabulin to treat NSCLC in combination with docetaxel."

According to principal investigator Dr Lyudmila Bazhenova, the trial intends to probe into Plinabulin's multiple mechanisms of action and its ability to target the tumour micro-environment, which will evaluate its efficacy as an immune-oncology agent.

See Also:

BeyondSpring chief medical officer Dr Ramon Mohanlal said: "This clinical trial provides additional research to assess the mechanism of Plinabulin in a combination treatment while collecting crucial information about the immune-related adverse events and preliminary efficacy profile of the combination.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"Our principal mission is focused on patient safety and developing an innovative and cost-effective oncology therapeutic to aid patients suffering from NSCLC, which accounts for approximately 85% of all lung cancer cases."

The company is currently conducting a global Phase III trial of plinabulin to treat NSCLC in combination with docetaxel.

Image: Micrograph displaying a form of NSCLC. Photo: courtesy of Nephron.